FDA Approved: ABILIFY MAINTENA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Abilify Maintena (aripiprazole) by Otsuka America Pharmaceutical, Inc., under NDA 202971.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABILIFY MAINTENA (ARIPIPRAZOLE)

Snippet

SUPPL AP for ABILIFY MAINTENA (ARIPIPRAZOLE)